Society News
-
IASLC Launches Career Advancement Grant to Expand Support for Mid-Career Researchers
By supporting multidisciplinary and global projects, the grant ensures mid-career professionals can continue contributing vital research to the field of lung and thoracic malignancies.
-
VERITAS Data Demonstrate Noninferiority of Navigational Bronchoscopy Compared to Transthoracic Needle Biopsy
Drs. James Katsis and William Thinnes say the safety profile and ability to stage lung cancer with a single procedure make a bronchoscopic approach the preferred method for lung nodule biopsy.
-
Beyond the Scalpel: Improving Lung Resection Outcomes with Enhanced Recovery After Surgery Protocols
Dr. Cezary T. Piwkowski says growing literature suggests that optimized preoperative preparation or “prehabilitation” is critical to improving early postoperative outcomes.
-
A Pragmatic Approach to Trial Design
Although the primary finding was not what investigators had hoped for, recent presentations by Drs. Karen Reckamp and Konstantin H. Dragnev highlighted Pragmatica-Lung’s success as a model for future trials.
-
In Brief: July 23, 2025
The US FDA grants Orphan Drug Designation to CID-078 for SCLC, and zidesamtinib demonstrates positive early data in ROS1-positive NSCLC.
-
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment.
-
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations.
-
In Brief for July 9, 2025
The FDA grants accelerated approval to Dato-DXd, while a Biologics License Application for HER3-DXd is voluntarily withdrawn.
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher.
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer.
View ILCN Archives
Provider Resources